Cellular distribution of injected PLGA-nanoparticles in the liver

The cellular fate of nanoparticles in the liver is not fully understood. Because the effectiveness and safety of nanoparticles in liver therapy depends on targeting nanoparticles to the right cell populations, this study aimed to determine a relative distribution of PLGA-nanoparticles (sizes 271±1.4 nm) among liver cells in vivo. We found that Kupffer cells were the major cells that took up nanoparticles, followed by liver sinusoidal endothelial cells and hepatic stellate cells. Nanoparticles were found in only 7% of hepatocytes. Depletion of Kupffer cells by clodronate liposomes increased nanoparticle retention in liver sinusoidal endothelial cells and hepatic stellate cells, but not in hepatocytes. It is importantly suggested that studies of drug-loaded nanoparticle delivery to the liver have to demonstrate not only uptake of nanoparticles by the target cell type but also non-uptake by other cell types to assess their effect as well as ensure their safety.

Summary of nanoparticle uptake in the liver.A hierarchy of nanoparticle (NP) uptake is seen among liver cells, which is characterized by dominance of Kupffer cells, followed by liver sinusoidal endothelial cells (LSECs), hepatic stellate cells (HSCs), and limited access to hepatocytes.Figure optionsDownload high-quality image (174 K)Download as PowerPoint slide